Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019

Respirol Case Rep. 2021 Mar 30;9(5):e00744. doi: 10.1002/rcr2.744. eCollection 2021 May.

Abstract

A 78-year-old Japanese woman with no smoking history suffered from near-fatal coronavirus disease 2019 (COVID-19) requiring four-week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post-COVID-19 fibrosis, although further studies are warranted.

Keywords: Acute respiratory distress syndrome; coronavirus disease 2019; nintedanib; pulmonary fibrosis; severe acute respiratory syndrome coronavirus 2.

Publication types

  • Case Reports